BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Horizon Pharma, Inc. Announces Pricing of Its Initial Public Offering


7/28/2011 8:51:38 AM

NORTHBROOK, IL--(Marketwire - July 28, 2011) - Horizon Pharma, Inc. (NASDAQ: HZNP) today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a price to the public of $9.00 per share. Horizon's common stock is scheduled to begin trading on The NASDAQ Global Market on July 28, 2011 under the symbol "HZNP." Horizon has also granted the underwriters a 30-day option to purchase up to an additional 825,000 shares at the initial public offering price to cover overallotments, if any.

Stifel Nicolaus Weisel, Cowen and Company and JMP Securities LLC are acting as joint bookrunners for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 28, 2011. The offering of these securities is being made only by means of a prospectus, copies of which may be obtained from: Stifel, Nicolaus & Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104, or by calling (415) 364-2720; Cowen and Company, LLC c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY,11717, Phone (631) 274-2806 / Fax (631) 254-7140; or JMP Securities LLC, 600 Montgomery Street, Suite 1100, San Francisco, CA 94111, or by calling (415) 835-8985.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

About Horizon Pharma
Horizon Pharma, Inc. is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. For more information, please visit www.horizonpharma.com.


Contacts
Robert J. De Vaere
Executive Vice President and Chief Financial Officer
Email Contact

Media
Geoff Curtis
Invigorate PR
312-646-6298
Email Contact

Investors
Kathy Galante
Burns McClellan, Inc.
212-213-0006
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES